236 related articles for article (PubMed ID: 27018596)
1. MEIS1-mediated transactivation of synaptotagmin-like 1 promotes CXCL12/CXCR4 signaling and leukemogenesis.
Yokoyama T; Nakatake M; Kuwata T; Couzinet A; Goitsuka R; Tsutsumi S; Aburatani H; Valk PJ; Delwel R; Nakamura T
J Clin Invest; 2016 May; 126(5):1664-78. PubMed ID: 27018596
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice.
Staffas A; Arabanian LS; Wei SY; Jansson A; Ståhlman S; Johansson P; Fogelstrand L; Cammenga J; Kuchenbauer F; Palmqvist L
Oncogene; 2017 Mar; 36(11):1516-1524. PubMed ID: 27617578
[TBL] [Abstract][Full Text] [Related]
3. Persistent transactivation by meis1 replaces hox function in myeloid leukemogenesis models: evidence for co-occupancy of meis1-pbx and hox-pbx complexes on promoters of leukemia-associated genes.
Wang GG; Pasillas MP; Kamps MP
Mol Cell Biol; 2006 May; 26(10):3902-16. PubMed ID: 16648484
[TBL] [Abstract][Full Text] [Related]
4. C-terminal domain of MEIS1 converts PKNOX1 (PREP1) into a HOXA9-collaborating oncoprotein.
Bisaillon R; Wilhelm BT; Krosl J; Sauvageau G
Blood; 2011 Oct; 118(17):4682-9. PubMed ID: 21900201
[TBL] [Abstract][Full Text] [Related]
5. Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus.
Wang GG; Pasillas MP; Kamps MP
Blood; 2005 Jul; 106(1):254-64. PubMed ID: 15755900
[TBL] [Abstract][Full Text] [Related]
6. The endothelin receptor type A is a downstream target of Hoxa9 and Meis1 in acute myeloid leukemia.
Arabanian LS; Johansson P; Staffas A; Nilsson T; Rouhi A; Fogelstrand L; Palmqvist L
Leuk Res; 2018 Dec; 75():61-68. PubMed ID: 30384975
[TBL] [Abstract][Full Text] [Related]
7. Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias.
Lawrence HJ; Rozenfeld S; Cruz C; Matsukuma K; Kwong A; Kömüves L; Buchberg AM; Largman C
Leukemia; 1999 Dec; 13(12):1993-9. PubMed ID: 10602420
[TBL] [Abstract][Full Text] [Related]
8. A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment.
Han AR; Lee JY; Kim HJ; Min WS; Park G; Kim SH
Oncol Rep; 2015 Dec; 34(6):2880-8. PubMed ID: 26398122
[TBL] [Abstract][Full Text] [Related]
9. The deficiency of tumor suppressor prep1 accelerates the onset of meis1- hoxa9 leukemogenesis.
Dardaei L; Modica L; Iotti G; Blasi F
PLoS One; 2014; 9(5):e96711. PubMed ID: 24809472
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of homeobox genes MEIS1 and HOXA in MLL-rearranged acute leukemia impairs engraftment and reduces proliferation.
Orlovsky K; Kalinkovich A; Rozovskaia T; Shezen E; Itkin T; Alder H; Ozer HG; Carramusa L; Avigdor A; Volinia S; Buchberg A; Mazo A; Kollet O; Largman C; Croce CM; Nakamura T; Lapidot T; Canaani E
Proc Natl Acad Sci U S A; 2011 May; 108(19):7956-61. PubMed ID: 21518888
[TBL] [Abstract][Full Text] [Related]
11. Pbx3 and Meis1 cooperate through multiple mechanisms to support Hox-induced murine leukemia.
Garcia-Cuellar MP; Steger J; Füller E; Hetzner K; Slany RK
Haematologica; 2015 Jul; 100(7):905-13. PubMed ID: 25911551
[TBL] [Abstract][Full Text] [Related]
12. Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia.
Mohr S; Doebele C; Comoglio F; Berg T; Beck J; Bohnenberger H; Alexe G; Corso J; Ströbel P; Wachter A; Beissbarth T; Schnütgen F; Cremer A; Haetscher N; Göllner S; Rouhi A; Palmqvist L; Rieger MA; Schroeder T; Bönig H; Müller-Tidow C; Kuchenbauer F; Schütz E; Green AR; Urlaub H; Stegmaier K; Humphries RK; Serve H; Oellerich T
Cancer Cell; 2017 Apr; 31(4):549-562.e11. PubMed ID: 28399410
[TBL] [Abstract][Full Text] [Related]
13. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
Li Z; Chen P; Su R; Hu C; Li Y; Elkahloun AG; Zuo Z; Gurbuxani S; Arnovitz S; Weng H; Wang Y; Li S; Huang H; Neilly MB; Wang GG; Jiang X; Liu PP; Jin J; Chen J
Cancer Res; 2016 Feb; 76(3):619-29. PubMed ID: 26747896
[TBL] [Abstract][Full Text] [Related]
14. Meis1 supports leukemogenesis through stimulation of ribosomal biogenesis and Myc.
Garcia-Cuellar MP; Prinz A; Slany RK
Haematologica; 2022 Nov; 107(11):2601-2616. PubMed ID: 35546301
[TBL] [Abstract][Full Text] [Related]
15. Meis1-mediated apoptosis is caspase dependent and can be suppressed by coexpression of HoxA9 in murine and human cell lines.
Wermuth PJ; Buchberg AM
Blood; 2005 Feb; 105(3):1222-30. PubMed ID: 15479723
[TBL] [Abstract][Full Text] [Related]
16. C/EBPα is an essential collaborator in Hoxa9/Meis1-mediated leukemogenesis.
Collins C; Wang J; Miao H; Bronstein J; Nawer H; Xu T; Figueroa M; Muntean AG; Hess JL
Proc Natl Acad Sci U S A; 2014 Jul; 111(27):9899-904. PubMed ID: 24958854
[TBL] [Abstract][Full Text] [Related]
17. Two isoforms of HOXA9 function differently but work synergistically in human MLL-rearranged leukemia.
He M; Chen P; Arnovitz S; Li Y; Huang H; Neilly MB; Wei M; Rowley JD; Chen J; Li Z
Blood Cells Mol Dis; 2012 Aug; 49(2):102-6. PubMed ID: 22633751
[TBL] [Abstract][Full Text] [Related]
18. ZAP-70 promotes the infiltration of malignant B-lymphocytes into the bone marrow by enhancing signaling and migration after CXCR4 stimulation.
Calpe E; Purroy N; Carpio C; Abrisqueta P; Carabia J; Palacio C; Castellví J; Crespo M; Bosch F
PLoS One; 2013; 8(12):e81221. PubMed ID: 24312539
[TBL] [Abstract][Full Text] [Related]
19. HOXA9 modulates its oncogenic partner Meis1 to influence normal hematopoiesis.
Hu YL; Fong S; Ferrell C; Largman C; Shen WF
Mol Cell Biol; 2009 Sep; 29(18):5181-92. PubMed ID: 19620287
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-708 is a novel regulator of the Hoxa9 program in myeloid cells.
Schneider E; Pochert N; Ruess C; MacPhee L; Escano L; Miller C; Krowiorz K; Delsing Malmberg E; Heravi-Moussavi A; Lorzadeh A; Ashouri A; Grasedieck S; Sperb N; Kumar Kopparapu P; Iben S; Staffas A; Xiang P; Rösler R; Kanduri M; Larsson E; Fogelstrand L; Döhner H; Döhner K; Wiese S; Hirst M; Keith Humphries R; Palmqvist L; Kuchenbauer F; Rouhi A
Leukemia; 2020 May; 34(5):1253-1265. PubMed ID: 31768018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
